Age-related osteoporosis is characterized by a decrease in bone-forming capacity mediated by defects in the number and function of osteoblasts. An important cellular mechanism that may in part explain osteoblast dysfunction that occurs with aging is senescence of mesenchymal progenitor cells (MPCs). In the telomere-based Wrn 2/2
INTRODUCTION
Skeletal aging of bone is characterized by loss of mineral content and microarchitectural changes that decrease bone strength and predispose bone to damage from repeated loading [1, 2] .
Osteoporosis is common in the Werner and dyskeratosis congenita premature aging syndromes, both characterized by telomere dysfunction [3, 4] . One of the targets of WRN helicase is telomeric DNA, but need for WRN at telomeres is minimized in mice by long telomeres and abundant telomerase, making Wrn knockout mice relatively unaffected [5, 6] . However, combining Wrn mutation with shortened telomeres of telomerase (Terc) knockout mice results in an accelerated aging model [5, 7] . Deficiencies in Wrn À/À Terc À/À mutant mice cause a low bone mass phenotype due to impaired osteoblast differentiation in the context of intact osteoclast differentiation [8, 9] . This impaired differentiation is associated with telomere dysfunction, as measured by the association of DNA damage proteins with telomeres in mesenchymal progenitor cells (MPCs) isolated from double mutant mice [9] . MPCs from Wrn À/À Terc À/À mutants have a reduced in vitro lifespan but also display impaired osteogenic potential with dysfunctional telomeres independently of proliferative state [9] . Here, we test the hypothesis that MPC aging contributes to bone loss in an accelerated aging mouse model that recapitulates many aspects of age-related bone loss.
MATERIALS AND METHODS
Detailed Materials and Methods are described in supporting information.
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Terc

2/2 Mutants Confers a Survival Advantage
To test the role of telomere-based MPC aging on age-related osteoporosis, Wrn À/À Terc À/À mutants were transplanted at 3 months of age with whole bone marrow (BM) from young wild-type donors. At 10.5 months after transplantation or when animals exhibited signs of significant distress and impending demise (whichever occurred first), mutants were sacrificed for analysis of functional MPC engraftment and concomitant measurements of skeletal microarchitectural features. As shown in Figure 1 , transplanted animals exhibited a survival advantage, having a mean life span approximately 30% longer than untransplanted controls (12.89 6 0.21 months vs. 10 6 0.57 months). This difference is particularly remarkable given that telomerase-deficient mice are hypersensitive to ionizing radiation and otherwise would have been expected to incur substantial harm from irradiation associated with bone marrow transplantation (BMT) [10] . Fig. S2 ). MPC functional engraftment is present up to 10.5 months after BMT. In femur sections from transplanted animals, 20% 6 8% of cortical osteocytes and 6% 6 2% of trabecular osteocytes were derived from engrafted precursors. Among endocortical and trabecular bone-lining osteoblasts, 15% 6 6% and 5% 6 1% were from precursors of donor origin, respectively. Differentiation of engrafted MPCs was most evident as endocortical osteocytes (supporting information Fig. S2 ). trabecular bone volume/total volume, trabecular number, or in cortical thickness (Fig. 4) . Interestingly, there was a statistically significant increase in the ratio of cortical area to total area, suggesting that transplanted mice were able to improve endocortical bone mass. Similarly, Wrn À/À Terc À/À BMT recipients had preserved osteoblasts/bone surface and no increase in the number of osteoclasts/bone surface (supporting information Fig. S3 ).
Long-Term Functional Engraftment of MPCs in Wrn
Delays in Microarchitectural Features
DISCUSSION
Although the causal role(s) of telomere dysfunction in agerelated osteoporosis are not completely established, there is evidence of its importance. Telomere lengthening mechanisms are not present in human BM MPCs [11] . Exogenous telomerase expression extends in vitro proliferative capacity, accelerates osteogenic differentiation, and enhances bone formation upon subcutaneous transplantation into mice [12, 13] . In addition, progeroid syndromes on which the Wrn À/À Terc À/À mutants are based (Werner syndrome and dyskerostis congenita, respectively) display premature osteoporosis [3, 4] . Although we cannot exclude that hematopoietic precursors including hematopoietic stem cells (HSCs), transplanted along with MPCs, may support mesenchymal engraftment and/or differentiation into cells of the osteoblast lineage, it is unlikely that CD45 À Sca-1 þ MPCs are derived directly from HSCs. However, there may be an early common BM progenitor for hematopoietic cells and osteoblasts delineated as [14, 15] . Soluble hematopoietic factors alone may be sufficient to exert effects on bone remodeling, or development of osteoblasts may depend on the proximity of hematopoietic cells. Sca-1, a cell-surface molecule also expressed on HSCs, appears to be necessary to maintain self-renewal of MPCs and suggests that the latter is plausible. In support of this, Sca-1 knockout mice develop age-dependent osteoporosis [16] . There could be systemic effects of BMT which may influence skeletal engraftment and differentiation of MPCs. Also, microenvironmental factors (including oxidative stress) may be at play. For example, we previously showed that osteoblast differentiation of MPCs from Wrn À/À Terc À/À mutants is rescued by reducing oxidative stress [9] . Increased oxidative stress favoring senescence in BM MPCs has also been postulated based on proteome screening of these cells from young and old rodents [17] . Muscle-derived stem/progenitor cells from young wild-type mice transplanted into a murine progeria model extended life span and improved degenerative changes in tissues where donor cells are not detected [18] . Although we cannot be sure that extraskeletal effects of BMT are responsible for life span extension in Wrn
À MPCs are present in bone tissue after long-term transplantation suggests that they play a role in maintenance of bone microarchitectural features over the period of extended survival.
To the extent that bone loss with physiologic aging involves telomere-based aging, our data indicate MPC senescence is a contributory mechanism. However, BMT as a therapeutic strategy may be limited by inadequate MPC engraftment [19] . It is debatable whether donor MPCs from human or mouse sources have sustained engraftment in host BM; however, our and other reports indicate that this is so [20] [21] [22] [23] [24] [25] [26] . Therefore, it is reasonable to suggest that decreased bone regeneration with age may be partially reversed by transplantation of young donor MPCs.
Wrn À/À Terc À/À mutants may have altered BM stroma which permits effective engraftment of donor MPCs. Thus BMT, performed for other reasons in telomere-based accelerated aging syndromes (e.g., aplastic anemia), may also confer beneficial effects in stabilizing or delaying premature osteoporosis. In fact, aplastic anemia in individuals with telomere-based progeroid syndromes may actually occur due to defective (telomerase-deficient) stroma which cannot support HSCs. Whole BMT in these patients may be successful [27] because it theoretically will correct both the stromal as well as the hematopoietic defects. 
CONCLUSIONS
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